Nalaganje...
Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity
BACKGROUND: Mirabegron is a β3-adrenergic receptor (β3-AR) agonist approved only for the treatment of overactive bladder. Encouraging preclinical results suggest that β3-AR agonists could also improve obesity-related metabolic disease by increasing brown adipose tissue (BAT) thermogenesis, white adi...
Shranjeno v:
| izdano v: | J Clin Invest |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
American Society for Clinical Investigation
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7190915/ https://ncbi.nlm.nih.gov/pubmed/31961826 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI131126 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|